top of page

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.410 +0.430 (+6.16%)

Streaming Delayed Price Updated: 2:02 PM EDT, Apr 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	15,668,742
Open	7.000
Bid (Size)	7.410 (2,000)
Ask (Size)	7.420 (3,800)
Prev. Close	6.980
Today's Range	6.980 - 7.640
52wk Range	1.830 - 12.43
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

Today 12:03 EDT

From SkyMedia, LLC

Via GlobeNewswire

ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue

Today 10:03 EDT

Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall...

Via Finterra

Performance

YTD	+266.8%	+266.8%
1 Month	-12.3%	-12.3%
3 Month	+236.8%	+236.8%
6 Month	+192.9%	+192.9%
1 Year	+206.2%	+206.2%

More News

Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBRX) to Contact the Firm Before Lead Plaintiff Deadline on May 26, 2026

Today 9:00 EDT

Via NewMediaWire

Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBRX) to Contact the Firm Before Lead Plaintiff Deadline on May 26, 2026

Today 9:00 EDT

Via TheNewswire.com

IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline

Today 8:23 EDT

From Bernstein Liebhard LLP

Via GlobeNewswire

ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

April 08, 2026

Via NewMediaWire

ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

April 08, 2026

Via TheNewswire.com

Kaplan Fox Alerts Investors of ImmunityBio, Inc. (IBRX) to a Securities Class Action Deadline on May 26, 2026

April 08, 2026

Via NewMediaWire

Kaplan Fox Alerts Investors of ImmunityBio, Inc. (IBRX) to a Securities Class Action Deadline on May 26, 2026

April 08, 2026

Via TheNewswire.com

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

April 07, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

April 07, 2026

From Pomerantz LLP

Via GlobeNewswire

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky

April 07, 2026

From Levi & Korsinsky, LLP

Via Business Wire

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

April 07, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 07, 2026

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

April 07, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Why ImmunityBio Stock Slumped on Monday ↗

April 06, 2026

Via The Motley Fool

ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit

April 06, 2026

Via NewMediaWire

ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit

April 06, 2026

Via TheNewswire.com

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

April 06, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit

April 05, 2026

Via TheNewswire.com

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit

April 05, 2026

Via NewMediaWire

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

April 04, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline

April 04, 2026

Via NewMediaWire

ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline

April 04, 2026

Via TheNewswire.com

Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

April 03, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 7.410

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 04/09/26 02:02 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 2.90B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

bottom of page